Additionally, Kurasawa et al.’s (17) research revealed a better survival rate of the refractory anti-MDA5-positive DM-ILD patients who were treated with the combination therapy, including tofacitinib, than that of the historical controls. Here, IFIH1 is linked to dermatomyositis.